Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification

Cancer Letters

Volumn 108, Issue 2, 1996, Pages 233-237

  States, J Christopher ^a   Reed, Eddie ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemoresistance; Cisplatin; DNA repair; Gene expression; Ovarian cancer; XPA

Indexed keywords

CISPLATIN; MESSENGER RNA;

ARTICLE; CLINICAL ARTICLE; EXCISION REPAIR; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 0030606304     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(96)04428-X     Document Type: Article

References (15)

1. [1] Asahina, H., Kuraoka, L, Shirakawa, M., Morita, E.H., Miura, N., Miyamoto, L, Ohtsuka, E., Okada, Y. and Tanaka, K. (1994) The XPA protein is a zinc metalloprotein with an ability to recognize various kinds of DNA damage, Mutat. Res. DNA Repair, 315, 229-237.
2. [2] Cleaver, J.E., Charles, W.C., McDowell, M.L., Sadinski, W.J. and Mitchell, D.L. (1995) Overexpression of the XPA repair gene increases resistance to ultraviolet radiation in human cells by selective repair of DNA damage, Cancer Res., 55, 6152-6160.
3. [3] Dabholkar, M., Vionnet, J., Bostickbruton, F., Yu, J.J. and Reed, E. (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy, J. Clin. Invest., 94, 703-708.
4. [4] Ferry, K.V., Ozols, R.F., Hamilton, T.C. and Johnson, S.W. (1996) Expression of nucleotide excision repair genes in CDDP-sensitive and resistant human ovarian cancer cell lines, Proc. Am. Assoc. Cancer Res., 37, 2492.
5. [5] Friedberg, E.C., Walker, G.C. and Siede, W. (1995) DNA Repair and Mutagenesis, ASM Press, Washington, D.C.
6. [6] Grompe, M. (1993) The rapid detection of unknown mutations in nucleic acids, Nature Genet., 5, 111-117.
7. [7] Li, L., Petersen, C.A., Lu, X. and Legerski, R.J. (1995) Mutations in XPA that prevent association with ERCC1 are defective in nucleotide excision repair, Mol. Cell. Biol., 15, 1993-1998.
8. [8] Liang, B.C., Ross, D.A. and Reed, E. (1995) Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas, J. Neuro-Oncol., 26, 17-23.
9. [9] Matsunaga, T., Mu, D., Park, C.H., Reardon, J.T. and Sancar, A. (1995) Human DNA repair excision nuclease: analysis of the roles of the subunits involved in dual incisions by using anti-XPG and anti-ERCC1 antibodies, J. Biol. Chem., 270, 20862-20869.
10. [10] Metzger, R., Danenberg, K., Hayashi, K., Lenz, H.J., Groshen, S., Leichman, C.G., Baranda, J., Crookes, P., Laine, L., Danenberg, P. and Leichman, L. (1996) ERCC1 expression correlates with response of primary gastric cancer to cisplatin-based chemotherapy, Proc. Am. Assoc. Cancer Res., 37, 1350.
11. [11] Reed, E. (1993) Anticancer drugs: platinum analogs. In: Cancer: Principles and Practice of Oncology, pp. 390-399. Editors: V.T. DeVita, Jr., S. Hellman and S.A. Rosenberg. Lippincott, Philadelphia.
12. [12] Satokata, I., Iwai, K., Matsuda, T., Okada, Y. and Tanaka, K. (1993) Genomic characterization of the human DNA excision repair-controlling gene Xpac, Gene, 136, 345-348.
13. [13] Topping, R.S., Myrand, S.P., Williams, B.L., Albert, J.C. and States, J.C. (1995) Characterization of the human XPA promoter, Gene, 166, 341-342.
14. [14] Van Oostrom, C.T.M., de Vries, A., Verbeek, S.J., van Kreiji, C.F. and van Steeg, H. (1994) Cloning and characterization of the mouse XPAC gene, Nucleic Acids Res., 22, 11-14.
15. [15] Zamble, D.B. and Lippard, S.J. (1995) Cisplatin and DNA repair in cancer chemotherapy, Trends Biochem Sci., 20, 435-439.